



IFW

CASE NO: ON0146A NP

**CERTIFICATE OF MAILING**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Brian C. Carey

Type or print name

Signature

May 23, 2006

Date

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****IN RE APPLICATION OF  
ROSOK ET AL.****Art Unit: 1645  
Examiner: S. DEVI****APPLICATION NO: 08/905,293****FILED: AUGUST 1, 1997****FOR: A METHOD FOR INHIBITING IMMUNOGLOBULIN-INDUCED  
TOXICITY RESULTING FROM THE USE OF IMMUNOGLOBULINS  
IN THERAPY AND IN VIVO DIAGNOSIS**

Assistant Commissioner for Patents  
Washington, D.C. 20231

**Amendment Under 37 C.F.R. §1.111 and  
Response to Notice to Comply**

Dear Sir,

In response to the May 8, 2006 "Notice to Comply With Requirement For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Disclosures," (hereinafter "Notice to Comply"), Applicants submit herewith: 1) a substitute computer readable form ("CRF") copy of a Sequence Listing and paper copy of the same; and 2) an amendment directing entry of the substitute Sequence Listing into the specification.

The time for responding is June 8, 2006, thus this response is timely filed. No fee is believed to be due at this time. Should the Office determine that fees are due, the Commissioner is hereby authorized to charge any additional fees under to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.